This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy with approved target drugs (dupilumab, tralokinumab, upadacitinib, abrocitinib, baricitinib) for AD will be enrolled. Patients already on therapy with these drugs will also be included. During the baseline and follow up visits, clinical and demographic data will be collected, according to ordinary clinical practice. Current or retrospective disease severity scores will also be collected. Among the main: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Dermatology Life Quality Index (DLQI), Pruritus Numerical Rating Scale (NRS pruritus), Sleep Numerical Rating Scale (NRS sleep), Patient Oriented Eczema Measure (POEM).
No linked publications found in PubMed
Inclusion Criteria: * Age 18 years or older * Diagnosed with moderate-to-severe atopic dermatitis (EASI\>24) * Undergoing therapy (retrospective cohort) or undertaking systemic therapy with a biological drug or small molecules * (for retrospective data) presence of at least one follow-up visit after the start of treatment for which clinical and demographic data were collected at baseline and follow-up visits. * Signature of informed consent to the study and to the processing of personal data for the research Exclusion Criteria: * Patients under 18 years of age * Patients who have undergone systemic therapy with a biological drug or small molecules for whom the start date of treatment is not available and/or no clinical-demographic data were collected at baseline and at follow-up visits. * Absence of informed consent to the study and processing of personal data for research purposes.